Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems

Thierry Burnouf, C. Caron, M. Radosevich, H. A. Goubran, J. Goudemand, M. El-ekiaby

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent-detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D-treated minipools of cryoprecipitates depleted of cryo-poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP-1% Triton X-45, followed by oil extractions (n =10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL-1 and 16.02 (±1.98) mg mL-1, and 8.92 (±1.05) IU mL-1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL-1, in those treated by TnBP-Triton X-45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL-1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD-treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti-A and anti-B titre was 0-1 and 0-1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.

Original languageEnglish
Pages (from-to)956-962
Number of pages7
JournalHaemophilia
Volume14
Issue number5
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Detergents
Octoxynol
von Willebrand Factor
Fibrinogen
Afibrinogenemia
von Willebrand Diseases
Factor VIII
Sodium Chloride
Plastics
Oils
Collagen
Safety
Antigens
Glucose
Proteins
factor VIII, von Willebrand factor drug combination

Keywords

  • Cryoprecipitate
  • Factor VIII
  • Fibrinogen
  • Minipool
  • Solvent-detergent
  • Virus
  • Von Willebrand factor

ASJC Scopus subject areas

  • Hematology

Cite this

Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. / Burnouf, Thierry; Caron, C.; Radosevich, M.; Goubran, H. A.; Goudemand, J.; El-ekiaby, M.

In: Haemophilia, Vol. 14, No. 5, 2008, p. 956-962.

Research output: Contribution to journalArticle

Burnouf, Thierry ; Caron, C. ; Radosevich, M. ; Goubran, H. A. ; Goudemand, J. ; El-ekiaby, M. / Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. In: Haemophilia. 2008 ; Vol. 14, No. 5. pp. 956-962.
@article{49b9f6e8f2d4420084b7ba7bf82b3bd2,
title = "Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems",
abstract = "Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent-detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D-treated minipools of cryoprecipitates depleted of cryo-poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2{\%} TnBP or 1{\%} TnBP-1{\%} Triton X-45, followed by oil extractions (n =10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL-1 and 16.02 (±1.98) mg mL-1, and 8.92 (±1.05) IU mL-1 in cryoprecipitate minipools treated with 2{\%} TnBP, and 17.26 (±1.71) mg mL-1, in those treated by TnBP-Triton X-45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL-1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD-treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti-A and anti-B titre was 0-1 and 0-1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.",
keywords = "Cryoprecipitate, Factor VIII, Fibrinogen, Minipool, Solvent-detergent, Virus, Von Willebrand factor",
author = "Thierry Burnouf and C. Caron and M. Radosevich and Goubran, {H. A.} and J. Goudemand and M. El-ekiaby",
year = "2008",
doi = "10.1111/j.1365-2516.2008.01797.x",
language = "English",
volume = "14",
pages = "956--962",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems

AU - Burnouf, Thierry

AU - Caron, C.

AU - Radosevich, M.

AU - Goubran, H. A.

AU - Goudemand, J.

AU - El-ekiaby, M.

PY - 2008

Y1 - 2008

N2 - Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent-detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D-treated minipools of cryoprecipitates depleted of cryo-poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP-1% Triton X-45, followed by oil extractions (n =10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL-1 and 16.02 (±1.98) mg mL-1, and 8.92 (±1.05) IU mL-1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL-1, in those treated by TnBP-Triton X-45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL-1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD-treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti-A and anti-B titre was 0-1 and 0-1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.

AB - Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent-detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D-treated minipools of cryoprecipitates depleted of cryo-poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP-1% Triton X-45, followed by oil extractions (n =10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL-1 and 16.02 (±1.98) mg mL-1, and 8.92 (±1.05) IU mL-1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL-1, in those treated by TnBP-Triton X-45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL-1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD-treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti-A and anti-B titre was 0-1 and 0-1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.

KW - Cryoprecipitate

KW - Factor VIII

KW - Fibrinogen

KW - Minipool

KW - Solvent-detergent

KW - Virus

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=51249116440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51249116440&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2008.01797.x

DO - 10.1111/j.1365-2516.2008.01797.x

M3 - Article

C2 - 18565126

AN - SCOPUS:51249116440

VL - 14

SP - 956

EP - 962

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 5

ER -